Clinical significance of human immunodeficiency virus type 1 replication fitness

被引:49
作者
Dykes, Carrie [1 ]
Demeter, Lisa M. [1 ]
机构
[1] Univ Rochester, Sch Med & Dent, Infect Dis Unit, Dept Med,Infect Dis Div, Rochester, NY 14642 USA
关键词
D O I
10.1128/CMR.00017-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The relative fitness of a vari ant, according to population genetics theory, is that variant's relative contribution to successive generations. Most drug-resistant human immunodeficiency virus type I (HTV-1) variants have reduced replication fitness, but at least some of these deficits can be compensated for, by the accumulation of second-site mutations. HIV-1 replication fitness also appears to influence the likelihood of a drug-resista, it mutant emerging during treatment failure and is postulated to influence clinical outcomes. A variety of assays are available to measure HIV-1 replication fitness in cell culture; however, there is no agreement regarding which assays best correlate with clinical outcomes. A major limitation is that there is no high-throughput assay that incorporates an internal reference strain as a control and utilizes intact virus isolates. Some retrospective studies have demonstrated statistically significant correlations between HTV-1 replication fitness and clinical outcomes in some patient populations. However, different studies disagree as to which clinical outcomes are most closely associated with fitness. This may be in part due to assay design, sample size limitations, and differences in patient populations. In addition, the strength of the correlations between fitness and clinical outcomes is modest, suggesting that, at present, it would be difficult to utilize these assays for clinical management.
引用
收藏
页码:550 / +
页数:30
相关论文
共 195 条
[1]   Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain [J].
Abram, ME ;
Parniak, MA .
JOURNAL OF VIROLOGY, 2005, 79 (18) :11952-11961
[2]  
Ait-Khaled M, 2003, ANTIVIR THER, V8, P111
[3]   Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages [J].
Aquaro, S ;
Svicher, V ;
Ceccherini-Silberstein, F ;
Cenci, A ;
Marcuccilli, F ;
Giannella, S ;
Marcon, L ;
Caliò, R ;
Balzarini, J ;
Perno, CF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (06) :872-878
[4]   Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture [J].
Archer, RH ;
Dykes, C ;
Gerondelis, P ;
Lloyd, A ;
Fay, P ;
Reichman, RC ;
Bambara, RA ;
Demeter, LM .
JOURNAL OF VIROLOGY, 2000, 74 (18) :8390-8401
[5]   The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNase H cleavages [J].
Archer, RH ;
Wisniewski, M ;
Bambara, RA ;
Demeter, LM .
BIOCHEMISTRY, 2001, 40 (13) :4087-4095
[6]   The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates [J].
Ariën, KK ;
Abraha, A ;
Quiñones-Mateu, ME ;
Kestens, L ;
Vanham, G ;
Arts, EJ .
JOURNAL OF VIROLOGY, 2005, 79 (14) :8979-8990
[7]  
Armand-Ugón M, 2003, ANTIVIR THER, V8, P1
[8]   MODE OF DIMERIZATION OF HIV-1 GENOMIC RNA [J].
AWANG, G ;
SEN, D .
BIOCHEMISTRY, 1993, 32 (42) :11453-11457
[9]   Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy [J].
Bacheler, LT ;
Anton, ED ;
Kudish, P ;
Baker, D ;
Bunville, J ;
Krakowski, K ;
Bolling, L ;
Aujay, M ;
Wang, XV ;
Ellis, D ;
Becker, MF ;
Lasut, AL ;
George, HJ ;
Spalding, DR ;
Hollis, G ;
Abremski, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2475-2484
[10]   Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme [J].
Back, NKT ;
Nijhuis, M ;
Keulen, W ;
Boucher, CAB ;
Essink, BBO ;
vanKuilenburg, ABP ;
vanGennip, AH ;
Berkhout, B .
EMBO JOURNAL, 1996, 15 (15) :4040-4049